Regina Schaffer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NEW ORLEANS — In the CLEAR Outcomes trial, bempedoic acid reduced risk for major CV events by 13% compared with placebo, including a 23% lower risk for MI, among adults with a history of CVD or at high risk deemed statin intolerant.Bempedoic acid (Nexletol, Esperion Therapeutics) was FDA approved in 2020 for lowering LDL, but the effects of the drug on CV outcomes have not been assessed,

PHILADELPHIA — Diabetes independently increases risk for cognitive decline, yet data from several large trials suggest GLP-1 receptor agonists hold significant promise to mitigate risk for dementia-related events, according to a speaker. “In addition to age and other risk factors, diabetes is a risk factor for cognitive decline, as is the degree of hyperglycemia,” Hertzel C.

NEW ORLEANS — A man with long-standing type 1 diabetes and no endogenous insulin production achieved insulin independence after an infusion of an investigational stem cell-derived pancreatic islet cell therapy, researchers reported.In a proof-of-concept study, treatment with half the target dose of VX-880 (Vertex Pharmaceuticals), a novel allogeneic stem cell-derived, fully differentiated,

NEW ORLEANS — Nearly all participants with obesity without diabetes assigned tirzepatide experienced at least 5% weight loss over 72 weeks compared with placebo, with at least 20% weight loss in more than half with the highest 15 mg dose.In the SURMOUNT-1 study, presented at the American Diabetes Association Scientific Sessions, researchers also noted a marked improvement in several key

WASHINGTON — In well-treated patients with chronic HF with reduced ejection fraction, omecamtiv mecarbil did not improve measures of exercise capacity over 20 weeks compared with placebo, researchers reported. Exercise is a “cardinal manifestation” of HF but is not improved by current medical therapies, G. Michael Felker, MD, MHS, professor of medicine at Duke Clinical Research